Oksana Tsyklauri is a highly experienced scientist currently serving as a Senior Scientist at PharmTheon and a Research and Development Expert at IOCB Prague since July 2023. With a robust background in immunology, Oksana has contributed significantly to the field, notably as the sole immunologist in a cross-functional team focused on developing novel NK cell cancer immunotherapy at IOCB Prague. Oksana's previous roles include Postdoctoral Research Fellow at the Institute of Molecular Genetics of the Czech Academy of Sciences, where four publications in high-impact journals enhanced understanding in T-cell immunology. Oksana holds a PhD in Immunology from Charles University and a Master's degree in Genetics from V. N. Karazin Kharkiv National University.
This person is not in any teams
This person is not in any offices
IOCB Prague - Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences
1 followers
The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB Prague) is a leading scientific institution in the Czech Republic, recognized internationally. Its primary mission is basic research in the fields of chemical biology and medicinal chemistry, organic and material oriented chemistry, chemistry of natural compounds, biochemistry and molecular biology, physical chemistry, theoretical chemistry, and analytical chemistry. Today, over 600 employees including 180 students in 45 research and service groups are involved in a broad spectra of disciplines, which results in more than 250 publications per year, including papers in the most cited prestigious journals such as Nature or Science. The Institute’s emphasis on interaction between chemistry and other sciences leads frequently to medicinal applications. An integral part of the mission of the Institute is, therefore, to transfer the scientific results into assets which help people to live better lives. Together with the research expertise, a system of technology transfer, IP management and commercialization have intensively been built-up. Through its subsidiary company IOCB TTO, the Institute helps scientists to transform ideas into patents and matches their research results with interests of commercial partners to bring novel ideas to human use or technology market.